Detalhe da pesquisa
1.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
N Engl J Med
; 389(10): 877-888, 2023 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351564
2.
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet
; 402(10400): 472-483, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369232
3.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab
; 25(9): 2642-2649, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37264711
4.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Diabetes Obes Metab
; 25(9): 2634-2641, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344954
5.
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
Diabetes Obes Metab
; 25(4): 1080-1090, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541037
6.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab
; 26(3): 1137, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37997518
7.
Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
Diabetes Obes Metab
; 26(2): 785-789, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37989596
8.
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
Diabetes Ther
; 15(4): 819-832, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402332
9.
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes.
J Diabetes Sci Technol
; 17(2): 274-282, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36575993
10.
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Diabetes Care
; 46(5): 998-1004, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857477
11.
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Lancet Diabetes Endocrinol
; 10(6): 418-429, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468322
12.
An unusual outbreak of hypoglycemia--a correction.
N Engl J Med
; 360(23): 2482-3, 2009 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-19494231
13.
An unusual outbreak of hypoglycemia.
N Engl J Med
; 360(7): 734-6, 2009 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-19213693
14.
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
J Med Chem
; 59(24): 10891-10916, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27749056
15.
Phaeochromocytoma mimicking scleroderma.
Int J Endocrinol
; 2011: 917453, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21423542
16.
Sequential imaging studies of cerebral gnathostomiasis with subdural hemorrhage as its complication.
Trans R Soc Trop Med Hyg
; 103(1): 102-4, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18951600